17th week of 2011 patent applcation highlights part 43 |
Patent application number | Title | Published |
20110098207 | Cellulase-Free Enzyme Compositions and Host Cells for Producing the Same - The present invention provides recombinant bacterial cells for producing a detergent-additive protein. In some embodiments, the cells are of the genus | 2011-04-28 |
20110098208 | METHOD FOR REDUCING THE ADHESION FORCES BETWEEN HARD SURFACES AND SUBSEQUENTLY OCCURRING SOIL - A method for reducing the adhesion forces between hard surfaces and subsequently occurring soil is described. The method comprises the step of treating the hard surfaces with a liquid composition comprising special copolymers A. These copolymers A comprise structural units originating from
| 2011-04-28 |
20110098209 | ENCAPSULATES - Encapsulates, compositions, packaged products and displays comprising such encapsulates, and processes for making and using such encapsulates, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs. | 2011-04-28 |
20110098210 | Environmentally Acceptable Dilutable Hard Surface Treatment Compositions - A dilutable concentrated hard surface cleaning composition which comprises (preferably consists essentially of): a detersive nonionic surfactant based on an alcohol alkoxylate; a detersive surfactant based on glucoside surfactants; an alkanolamine; water in an amount of at least 75% wt., preferably at least about 80% wt., and optionally one or more further optional constituents, including a polyacrylate polymer, fragrances, colorants, etc. with the proviso that the compositions exclude one or more of: (a) organic acids, (b) inorganic acids, (c) organic solvents selected from glycols, glycol ethers, ether acetates, and alcohols, (d) thickeners, and (e) chelating agents based on nitrogen containing organic compounds which include a plurality of carboxylic acid groups, preferably the compositions of the invention expressly exclude two or more, preferably three or more and yet more preferably exclude four or five of (a), (b), (c), (d) and (e). | 2011-04-28 |
20110098211 | MUTEINS WITH TEAR LIPOCALIN HAVING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS FOR OBTAINING THE SAME - The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein. | 2011-04-28 |
20110098212 | CYTOKINE - A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described. | 2011-04-28 |
20110098213 | Novel peptides for use in the treatment of obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2011-04-28 |
20110098214 | LPS OR LIPID A BINDING AGENT AND NOVEL PEPTIDE - A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS and/or lipid A binding agent is useful as, for example, an LPS and/or lipid A neutralizing agent or an LPS and/or lipid A removing agent. | 2011-04-28 |
20110098215 | PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS - Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof. | 2011-04-28 |
20110098216 | THERAPEUTIC USES OF COLOSTRININ - There is provided the use of Colostrinin for the treatment of obesity. | 2011-04-28 |
20110098217 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY - Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized. | 2011-04-28 |
20110098218 | MODULATORS OF STAT3 SIGNALLING - The invention relates to methods for identifying compounds which modulate the interaction between STAT3 an SP1. A peptide is provided which is able to bind STAT3 and interfere with the interaction of STAT3 and SP1. The invention provides methods for identifying compounds which are capable of binding to the peptide and thus release interference with the interaction between STAT3 and SP1, as well as methods for identifying inhibitors and enhancers of the STAT3 SP1 interaction. Compounds identified by the methods of the invention are useful in the repression or stimulation of appetite in a patient, useful for the treatment of leptin resistance, obesity and anorexia. | 2011-04-28 |
20110098219 | System for Curing Hepatic Cancer with Leptin - The present invention cures hepatic cancer by MPA with the help of leptin. A therapeutic drug of MPA combined with leptin is applied to a liver cancer patient. Or, MPA can be directly applied to a patient having a high leptin expression. Or, if a patient has a low leptin expression, MPA is applied to the patient after leptin expression is increased. Hence, expression of leptin can be taken as a predictive factor and a prognostic factor of treatment effect on curing the patient with MPA. | 2011-04-28 |
20110098220 | METHODS AND KITS FOR PREVENTING HYPOGLYCEMIA - The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy. | 2011-04-28 |
20110098221 | INHIBITORS OF Akt ACTIVITY - Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2011-04-28 |
20110098222 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues. | 2011-04-28 |
20110098223 | USE OF THE PAT NANOPEPTIDE IN THE TREATMENT OF AUTOIMMUNE DISEASES - The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease. | 2011-04-28 |
20110098224 | PROTEIN KINASE C PEPTIDE MODULATORS OF ANGIOGENESIS - The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. The peptides can be used to inhibit angiogenesis and/or vascular permeability. The peptides can be used to treat subjects having, for example, cancer, diabetic blindness, macular degeneration, rheumatoid arthritis, or psoriasis. | 2011-04-28 |
20110098225 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) - The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role. | 2011-04-28 |
20110098226 | Small molecular weight TNF receptor multimeric molecule - The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct. The invention also relates to a method of inhibiting the biological activity of TNF in a host comprising administering to the host an effective amount of a receptor molecule of the present invention. The invention further relates to receptor molecules which bind cytokines that bind to receptor molecules comprising more than one subunit. | 2011-04-28 |
20110098227 | Soluble notch-based substrates for gamma secretase and methods and compositions for using same - The present invention is directed to novel soluble substrates for γ-secretase. More particularly, the invention provides a soluble fusion polypeptide with a Notch segment containing the γ-secretase-dependent cleavage sites (γ and ε) fused to a NusA protein. Methods and compositions for making and using such a fusion protein are disclosed. | 2011-04-28 |
20110098228 | SYNTHETIC ANALOGUES OF NEURAL REGENERATION PEPTIDES - Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing β-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis. | 2011-04-28 |
20110098229 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS - Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid. | 2011-04-28 |
20110098230 | COSMETIC USE OF ANNEXIN II-TYPE PROTEINS FOR TREATING DRYNESS OF THE SKIN - The present invention relates to the use, in particular cosmetic and/or therapeutic use, of annexin II, of polypeptides derived from this protein or of analogues thereof, of a nucleic sequence encoding such a polypeptide or of a modulator of the activity, the stability or the expression of such a polypeptide, in particular for preventing and/or treating the signs of skin dryness. | 2011-04-28 |
20110098231 | Skin Cosmetic - A skin cosmetic comprising the following ingredients (A), (B), and (C), and also satisfying the condition (D):
| 2011-04-28 |
20110098232 | Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis - Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation. | 2011-04-28 |
20110098233 | HLA-A* 1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention relates to an HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a | 2011-04-28 |
20110098234 | BREAST CANCER PROTEINS - The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors. | 2011-04-28 |
20110098235 | ANTINEOPLASTIC PEPTIDES - The present invention provides antineoplastic peptides of formula I, | 2011-04-28 |
20110098236 | DIAMIDE INHIBITORS OF CYTOCHROME P450 - Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes. | 2011-04-28 |
20110098237 | METHODS FOR INHIBITING DRUG DEGRADATION - Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes. | 2011-04-28 |
20110098238 | ELUCIDATING LIGAND-BINDING INFORMATION BASED ON PROTEIN TEMPLATES - A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that can be used to screen libraries of compounds for individual compounds that are predicted to have high binding affinities for the target protein. | 2011-04-28 |
20110098239 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF - The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases. | 2011-04-28 |
20110098240 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR - The invention relates to a pharmaceutical composition according to claim | 2011-04-28 |
20110098241 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS - Analogs and derivatives of rapamycin are provided, wherein the analogs and derivatives can bind to FK-506 binding protein (FKBP), or inhibit the mTOR function of an FKBP, or both. The analogs and derivatives are rapamycin include the rapamycin skeleton substituted at the 42-hydroxyl group with certain specified chemically feasible groups. Methods of using the rapamycin analogs and derivatives in treatment of malconditions such as cancer, and methods of synthesizing the rapamycin analogs and derivatives, are provided. | 2011-04-28 |
20110098242 | Methods and Compositions for Diagnosing and Treating Cervical Intraepithelial Neoplasia and Cervical Cancer - Disclosed herein are methods and compositions for diagnosing and treating diseases associated with a loss of cystatin E/M expression including cervical intraepithelial neoplasia and cervical cancer. Genetic mutations and exonic deletions which result in a loss of cystatin E/M expression are also disclosed. | 2011-04-28 |
20110098243 | ECTONUCLEOTIDASE PYROPHOSPHATE/PHOSPHODIESTERASE-1 (ENPP-1) AS A TARGET FOR THE TREATMENT OF AORTIC VALVE STENOSIS AND CARDIOVASCULAR CALCIFICATION - Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP activity with ARL 67156 significantly reduced calcification of isolated valve interstitial cells. In a rat model of cardiovascular calcification, ARL 67156 significantly reduced calcification of the aortic root and valve cusps. This is the first study to demonstrate that increased expression and activity of ENPP-1 promotes the mineralization process in AS valves. Hence, inhibition of ectonucleotidase may represent a novel target of therapy for this frequent and serious cardiovascular disease. | 2011-04-28 |
20110098244 | Process for Isolating Sialic Acid Containing Oligosaccharides, and the Compositions Containing Sialic Acid Containing Oligosaccharides Obtainable Thereby - The invention relates to a process for isolating sialic acid containing oligosaccharides and in particular sialyllactose from a milk stream and especially from a whey stream. The process yields a product having a high content of sialyllactose and a low content of phosphorus compounds. This product is highly suitable to be included in infant foods. | 2011-04-28 |
20110098245 | AGENT FOR PREVENTING OR AMELIORATING OBESITY - The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate. | 2011-04-28 |
20110098246 | METHOD FOR PREVENTING CORTICOSTEROID USAGE - The present invention relates to the use of nutritional compositions comprising non-digestible oligosaccharides for preventing corticoid administration, particularly to infants. | 2011-04-28 |
20110098247 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors - Compounds of formula I are provided: | 2011-04-28 |
20110098248 | MODULATORS OF TOLL-LIKE RECEPTORS - The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds. | 2011-04-28 |
20110098249 | COMPOSITIONS AND METHODS OF TREATMENT FOR ALLEVIATING PREMENSTRUAL SYNDROME SYMPTOMS - The present invention discloses pharmaceutical/nutritional compositions for alleviating symptoms associated with premenstrual syndrome (PMS) and methods of treatment for PMS using such pharmaceutical/nutritional composition including: at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total composition, as an effective ingredient, wherein: the phosphatidyl-L-serine has a structural fatty-acid chain derived from at least one raw material lecithin. Preferably, the phosphatidyl-L-serine is produced by enzymatic reaction of at least one raw material lecithin with phospholipase-D; at least one raw material lecithin is selected from the group consisting of: a vegetal lecithin and a non-vegetal lecithin; and the phospholipase-D is selected from the group consisting of: vegetal phospholipase-D, bacterial-originated enzyme phospholipase-D, and a combination of vegetal phospholipase-D and bacterial-originated enzyme phospholipase-D. Preferably, the structural fatty-acid chain is a saturated, hydrogenated fatty-acid chain. Preferably, the phosphatidyl-L-serine is derived from a dairy lecithin. | 2011-04-28 |
20110098250 | WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION - The present invention provides a benzoazepine compound represented by following general formula (1): | 2011-04-28 |
20110098251 | BISPHOSPHONATE COMPOUNDS - Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism. | 2011-04-28 |
20110098252 | Treatment of Spinal Mechanical Pain - The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate. | 2011-04-28 |
20110098253 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use - The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. | 2011-04-28 |
20110098254 | COMPOSITIONS COMPRISING PHOSPHOLIPIDS - The present invention provides compositions comprising phospholipids and particularly those comprising at least 40% phospholipid and at least 80% phospholipid as a percentage of total fat in the extract, comprising polyunsaturated and saturated phospholipids, in a ratio of saturated phospholipid to monounsaturated to polyunsaturated phospholipid of about 6:3:1 respectively, or comprising at least 40% phospholipid and less than 40% protein and methods for their production from dairy products. | 2011-04-28 |
20110098255 | COMBINATION OF A PARP INHIBITOR AND AN AKT KINASE ACTIVATING COMPOUND - The primary subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination in the treatment of pathological conditions related to PARP activation and/or that could benefit from Akt activation. A further subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination for the preparation of pharmaceutical composition or kit for the treatment of a pathological condition related to PARP activation. The invention also relates to pharmaceutical composition, which contains a PARP-inhibitor and an Akt kinase activating compound together with auxiliaries generally used in pharmacy. | 2011-04-28 |
20110098256 | Method for making and using a topical dermatological solution - A novel method for making and using topical dermatological solution for external use which is effective in treating dermatological disorders. The methods include administering a therapeutically effective amount of a topical dermatological solution comprising pre-mixed agents which can affect a variety of inflammatory conditions of the skin thus treating a variety of minor skin irritations resulting from an array of causes such as dermatitis, insect bites, skin rash, plant poisoning, acne, pimples, folliculitis, sunburn, burns, and the like. The method for making this unique curative solution includes mixing particular proportions of aspirin, white vinegar, table salt, and baking soda. The present invention further provides a topical dermatological solution and a method for applying the topical dermatological solution to the skin from a single dispensing and applicator sheet, wherein said solution is released from the sheet and applied to the afflicted skin area. | 2011-04-28 |
20110098257 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID - The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer. | 2011-04-28 |
20110098258 | Transdermal Pharmaceutical Compositions Comprising Active Agents - The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent. | 2011-04-28 |
20110098259 | PREGNANE STEROIDS AND THEIR USE IN THE TREATMENT OF CNS DISORDERS - Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders. | 2011-04-28 |
20110098260 | Steroid Compounds and Formulations - The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications. | 2011-04-28 |
20110098261 | TRITERPENOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS - The present invention relates to the use of triterpenoid-based compounds of formula (1) for inhibiting viral activity. The triterpenoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases. | 2011-04-28 |
20110098262 | CORROLES FOR NEUROPROTECTION AND NEURORESCUE - Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF | 2011-04-28 |
20110098263 | HYDROXY-SUBSTITUTED COLD(III) PORPHYRIN COMPLEXES AS HISTONE DEACETYLASE INHIBITORS - A method for treatment of cancer by inhibiting the activity of histone deacetylase, comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of a gold(III) complex having the structural formula of | 2011-04-28 |
20110098264 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT - The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase. | 2011-04-28 |
20110098265 | METHODS FOR REDUCING CRAVINGS AND IMPULSES ASSOCIATED WITH ADDICTIVE AND COMPULSIVE BEHAVIORS - This document provides methods and materials related to managing weight, supporting appetite control, and controlling cravings associated with smoking reduction or cessation regimens and/or nicotine reduction or cessation regimens. For example, compositions comprising an agent to support acetylcholine and an agent to support one or more biogenic amines, and methods for using such compositions for craving and appetite control are provided. Methods and materials to reduce cravings associated with the reduction or cessation of the use of chemical substances (e.g., drugs of abuse, including opioids, cocaine, methamphetamine, cannabis, alcohol), and to reduce cravings associated with addictive and/or compulsive behaviors (e.g., gambling, sex, and repetitive behaviors) are also provided. | 2011-04-28 |
20110098266 | METHOD OF ADMINISTERING AN INJECTABLE ANTIBIOTIC TO AN ANIMAL - A method of administering an antibiotic to an animal in need thereof, including the step of injecting the antibiotic subcutaneously at the junction of a pinna with the cranium of the animal, is disclosed. | 2011-04-28 |
20110098267 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS - The invention relates to a topical composition and a method for treating psoriasis. The topical composition comprises one or more compound that inhibits the production of IL-12 and IL-23. | 2011-04-28 |
20110098268 | SPIROCYCLIC COMPOUNDS - The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 2011-04-28 |
20110098269 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands - The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII: | 2011-04-28 |
20110098270 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE - Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. | 2011-04-28 |
20110098271 | CHROMENONE DERIVATIVES - The invention concerns chromenone derivatives of Formula I | 2011-04-28 |
20110098272 | Novel Compounds As Casein Kinase Inhibitors - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I | 2011-04-28 |
20110098273 | Oligomer-Calcium Channel Blocker Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer. | 2011-04-28 |
20110098274 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS - Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. | 2011-04-28 |
20110098275 | 5-ALKYNYL-PYRIDINES - The present invention encompasses compounds of general formula (1) | 2011-04-28 |
20110098276 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF - The invention relates to oxycarbamoyl compounds of Formula I: | 2011-04-28 |
20110098277 | Fab I Inhibitors - Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections. | 2011-04-28 |
20110098278 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF - Prodrugs of galantamine or its 3-hydroxy metabolite with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and methods for treating a memory or cognition disorder with the galantamine prodrugs are provided herein. Prodrugs having side chains of valine, phenylalanine, tyrosine or para amino benzoic acid and mono-, di- and tripeptides thereof are preferred. Additionally, methods for avoiding or minimizing the adverse gastrointestinal side effects associated with galantamine administration, as well as improving the pharmacokinetics of galantamine are provided herein. | 2011-04-28 |
20110098279 | USE OF TRIAZOLOPYRIMIDINE DERIVATIVES AS MICROBICIDES - Use of compounds of the formula (I) | 2011-04-28 |
20110098280 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS - Novel pyrimidine derivatives of formula I | 2011-04-28 |
20110098281 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 2011-04-28 |
20110098282 | NEW COMPOUNDS - Novel compounds of which the following is exemplary: | 2011-04-28 |
20110098283 | 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER - The invention relates to chemical compounds of formula (I): | 2011-04-28 |
20110098284 | Methods and compositions for treating pain - The present invention provides a method of treating or preventing pain, inflammation or fever comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more selected NSAIDs, in racemic, enantiomeric excess, or enantiomeric form, in combination with ethylenediamine and/or piperazine. | 2011-04-28 |
20110098285 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS - Compounds of formula (I) | 2011-04-28 |
20110098286 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2011-04-28 |
20110098287 | Novel Heteroaromatic Amides And Thioamides As Pesticides - The present application relates to novel amides and thioamides, to processes for preparation thereof and to use thereof for controlling animal pests, in particular arthropods and especially insects. | 2011-04-28 |
20110098288 | SULFONAMIDES AS ZAP-70 INHIBITORS - The invention relates to compounds of formula (I) | 2011-04-28 |
20110098289 | METHOD FOR TREATING OBESITY - The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism. | 2011-04-28 |
20110098290 | PHARMACEUTICAL COMPOUNDS - The invention provides a compound of the formula (1): | 2011-04-28 |
20110098291 | ANTAGONIST OF SMOOTHENED - Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary diseases and disorders. | 2011-04-28 |
20110098292 | New Compounds Useful for Treating CNS Disorders - The present invention provides new compounds of formula (I) as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy. | 2011-04-28 |
20110098293 | Inhibitors of Protein Tyrosine Kinase Activity - This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions. | 2011-04-28 |
20110098294 | PURINE ANALOGS - The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals. | 2011-04-28 |
20110098295 | METHODS OF TREATING ANXIETY, ITCHING AND PSYCHIATRIC DISORDERS - A method of treating an undesirable AC8-related condition in a mammal is provided comprising the step of inhibiting AC8 in the mammal | 2011-04-28 |
20110098296 | Thiazole And Oxazole Kinase Inhibitors - The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. | 2011-04-28 |
20110098297 | FUSED RING COMPOUNDS AND USE THEREOF - The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof. | 2011-04-28 |
20110098298 | New Pyridin-3-Amine Derivatives - This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) | 2011-04-28 |
20110098299 | SPIROLACTAM DERIVATIVES AND USES OF SAME - The present invention provides spirolactam derivatives of formula (I): | 2011-04-28 |
20110098300 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and; memory disorders, cognitive disorders, attention deficit disorder, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, dementia, depression, epilepsy, seizures, convulsions, sleep/wake and arousal/vigilance disorders such as hypersomnia and narcolepsy, pain and/or obesity. | 2011-04-28 |
20110098301 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders - Pyrimidine derivatives of formula | 2011-04-28 |
20110098302 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 2011-04-28 |
20110098303 | Method of promoting nail growth using thyromimetic compounds - The present invention provides methods and compositions for increasing the rate of nail growth in mammals, especially humans, using thyromimetic compounds. | 2011-04-28 |
20110098304 | Small molecule inhibitors of PARP activity - Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such componds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer. | 2011-04-28 |
20110098305 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 2011-04-28 |
20110098306 | Uses of tetrahydrobiopterin, sepiapterin and derivatives thereof - The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor. | 2011-04-28 |